Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.)
National trade organization representing the interests of generic drug manufacturers.
Based in DC
🤖
AI Overview
With $1.5M in lobbying spend across 32 quarterly filings, Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) is a significant lobbying presence.
$1.5M
Total Lobbying Spend
32
Quarterly Filings
1
Lobbying Firms Used
7
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $150K |
| 2019 | $200K |
| 2020 | $190K |
| 2021 | $160K |
| 2022 | $240K |
| 2023 | $160K |
| 2024 | $200K |
| 2025 | $180K |
Lobbying Firms
CAPITOL HILL CONSULTING GROUP
What They Lobby For
- - Issues relating to bioequivalence and related administrative procedures. - Issues relating to prescription drug abuse. - Issues relating to the labeling of generic drugs. - FAST Generics Act / CREATES Act of 2017 concerning REMS - Issues related to H.R. 1628, the American Health Care Act. - Issues related to H.R. 1625, the Consolidated Appropriations Act of 2018
- Issues related to tax reform concerning Border Adjustment Tax
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program. Issues related to the Medicare low-income subsidy. Issues related to the cost of prescription drugs. Issues pertaining to coverage and reimbursement of biosimilars.
- - Issues relating to bioequivalence and related administrative procedures. - Issues relating to prescription drug abuse. - Issues relating to the labeling of generic drugs. - FAST Generics Act / CREATES Act of 2017 concerning REMS - Issues related to H.R. 1628, the American Health Care Act.
- Issues relating to coverage of genetics and biosimilars as part of USMCA
- - Issues relating to bioequivalence and related administrative procedures. - Issues relating to prescription drug abuse. - Issues relating to the labeling of generic drugs. - FAST Generics Act / CREATES Act of 2017 concerning REMS - Issues related to H.R. 1628, the American Health Care Act.
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program. Issues related to the Medicare low-income subsidy. Issues related to the cost of prescription drugs. Issues pertaining to coverage and reimbursement of biosimilars.
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program. Issues related to the Medicare low-income subsidy. Issues related to the cost of prescription drugs. Issues pertaining to coverage and reimbursement of biosimilars. Issues related to Part D coverage of generic drugs, including Part D redesign.
- - Issues relating to bioequivalence and related administrative procedures. - Issues relating to prescription drug abuse. - Issues relating to the labeling of generic drugs. - FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues relating to coverage of generics and biosimilars as part of USMCA
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.